**Mayo Clinic Brain Tumor Patient-Derived Xenograft National Resource - Manuscript List**

<https://www.mayo.edu/research/labs/translational-neuro-oncology/mayo-clinic-brain-tumor-patient-derived-xenograft-national-resource/overview>

**Updated February 2023**

1. Ngo MT, Sarkaria JN, Harley BAC. Perivascular Stromal Cells Instruct Glioblastoma Invasion, Proliferation, and Therapeutic Response within an Engineered Brain Perivascular Niche Model. Adv Sci (Weinh). 2022 Nov;9(31):e2201888. PMCID: PMC9631060.
2. Talele S, Zhang W, Chen J, et al. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. J Pharmacol Exp Ther. 2022 Oct;383(1):91-102. PMCID: PMC9513858.
3. Rechberger JS, Porath KA, Zhang L, et al. IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. Pharmaceutics. 2022 Apr 24;14(5):922. PMCID: PMC9143740.
4. Rahman M, Olson I, Mansour M, et al. Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. Mol Cancer Res. 2022 Jun 3;20(6):938-48. PMCID: PMC9196639.
5. Chen JE, Leary S, Barnhouse V, Sarkaria JN, Harley BAC. Matrix Hyaluronic Acid and Hypoxia Influence a CD133+ Subset of Patient-Derived Glioblastoma Cells. Tissue Eng Part A. 2022 Apr;28(7-8):330-40. PMCID: PMC9057908.
6. Burgenske DM, Talele S, Pokorny JL, et al. Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. Neuro Oncol. 2022 Mar 12;24(3):384-95. PMCID: PMC8917401.
7. Porath KA, Regan MS, Griffith JI, et al. Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts. Neurooncol Adv. 2022 Aug 24;4(1):vdac130. PMCID: PMC9446689.
8. Lopez BGC, Kohale IN, Du Z, et al. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2022 Jan 5;24(1):64-77. PMCID: PMC8730776.
9. McCord M, Bartom E, Burdett K, et al. Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. Cancers (Basel). 2022 Nov 9;14(22):5494. PMCID: PMC9688760.
10. Mladek AC, Yan H, Tian S, et al. RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. Neuro Oncol. 2022 Aug 1;24(8):1261-72. PMCID: PMC9340617.
11. Kizilbash SH, Gupta SK, Parrish KE, et al. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Mol Cancer Ther. 2021;20(6):1009-18 PMCID: PMC8172524.
12. Jermakowicz AM, Rybin MJ, Suter RK, et al. The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion. Sci Rep. 2021;11(1):23370 PMCID: PMC8642539.
13. Yeo AT, Jun HJ, Appleman VA, et al. EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma. Oncogene. 2021;40(15):2682-96.
14. Kenchappa RS, Liu Y, Argenziano MG, et al. Protein kinase Ciota and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. Cell Rep. 2021;37(8):110054.
15. Seguin L, Odouard S, Corlazzoli F, et al. Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. Commun Biol. 2021;4(1):718 PMCID: PMC8192788.
16. Talele S, Zhang W, Burgenske DM, et al. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. J Pharmacol Exp Ther. 2021;379(3):343-57.
17. Monie DD, Bhandarkar AR, Parney IF, et al. Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma. Neurosurg Focus. 2021;50(2):E10 PMCID: PMC8193210.
18. Marin BM, Porath KA, Jain S, et al. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro Oncol. 2021;23(12):2042-53 PMCID: PMC8643472.
19. Rajani K, Olson I, Jacobs JJ, et al. Methods for intratumoral microdialysis probe targeting and validation in murine brain tumor models. J Neurosci Methods. 2021;363:109321.
20. Burgenske DM, Talele S, Pokorny JL, et al. Preclinical modeling in GBM PDX xenografts to guide clinical development of lisavanbulin - a novel tumor checkpoint controller targeting microtubules. Neuro Oncol. 2021.
21. B GCL, Kohale IN, Du Z, et al. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2021.
22. Eckel-Passow JE, Kitange GJ, Decker PA, et al. Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines. Neuro Oncol. 2021;23(12):2066-75 PMCID: PMC8643474.
23. Zhou W, Yao Y, Scott AJ, et al. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nat Commun. 2020;11(1):3811 PMCID: PMC7393131.
24. Renfrow JJ, Soike MH, West JL, et al. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020;10(1):15195 PMCID: PMC7495485.
25. Angom RS, Mondal SK, Wang F, et al. Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme. Oncogene. 2020;39(48):7114-26.
26. Chen JE, Lumibao J, Leary S, et al. Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model. Journal of neuroinflammation. 2020;17(1):346 PMCID: PMC7677841.
27. Connor K, Murray DW, Jarzabek MA, et al. Targeting the RhoGEF betaPIX/COOL-1 in Glioblastoma: Proof of Concept Studies. Cancers. 2020;12(12).
28. Werner CK, Nna UJ, Sun H, et al. Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Mol Cancer Ther. 2020;19(10):2163-74.
29. Massey SC, Urcuyo JC, Marin BM, Sarkaria JN, Swanson KR. Quantifying Glioblastoma Drug Response Dynamics Incorporating Treatment Sensitivity and Blood Brain Barrier Penetrance From Experimental Data. Frontiers in physiology. 2020;11:830 PMCID: PMC7472531.
30. Benavides-Serrato A, Saunders JT, Holmes B, et al. Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma. Int J Mol Sci. 2020;21(1) PMCID: PMC6981868.
31. Ramakrishnan V, Xu B, Akers J, et al. Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas. EBioMedicine. 2020;55:102736 PMCID: PMC7195524.
32. Gupta K, Vuckovic I, Zhang S, et al. Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma. Front Oncol. 2020;10:535 PMCID: PMC7214818.
33. Vaubel RA, Tian S, Remonde D, et al. Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clin Cancer Res. 2020;26(5):1094-104 PMCID: PMC7056576.
34. Basu SS, Regan MS, Randall EC, et al. Rapid MALDI mass spectrometry imaging for surgical pathology. NPJ Precis Oncol. 2019;3:17 PMCID: PMC6609678.
35. Inglut CT, Baglo Y, Liang BJ, et al. Systematic Evaluation of Light-Activatable Biohybrids for Anti-Glioma Photodynamic Therapy. J Clin Med. 2019;8(9) PMCID: PMC6780262.
36. Harder BG, Peng S, Sereduk CP, et al. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. Mol Med. 2019;25(1):49 PMCID: PMC6854621.
37. Nguyen TTT, Ishida CT, Shang E, et al. Activation of LXRbeta inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibition. EMBO Mol Med. 2019;11(10):e10769 PMCID: PMC6783693.
38. Stalinska J, Zimolag E, Pianovich NA, et al. Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential. Transl Oncol. 2019;12(7):895-907 PMCID: PMC6514324.
39. Roos A, Dhruv HD, Peng S, et al. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival. Mol Cancer Res. 2018;16(7):1185-95 PMCID: PMC6030495.
40. Ding Z, Dhruv H, Kwiatkowska-Piwowarczyk A, et al. PDZ-RhoGEF Is a Signaling Effector for TROY-Induced Glioblastoma Cell Invasion and Survival. Neoplasia. 2018;20(10):1045-58 PMCID: PMC6140379.
41. Zhao SG, Yu M, Spratt DE, et al. Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro Oncol. 2019.
42. Loskutov YV, Griffin CL, Marinak KM, et al. LPA signaling is regulated through the primary cilium: a novel target in glioblastoma. Oncogene. 2018;37(11):1457-71 PMCID: PMC5854509.
43. Herrera-Perez RM, Voytik-Harbin SL, Sarkaria JN, et al. Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition. PLoS One. 2018;13(3):e0194183 PMCID: PMC5863989.
44. Zhou D, Alver BM, Li S, et al. Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol. 2018;19(1):43 PMCID: PMC5872397.
45. Jun HJ, Appleman VA, Wu HJ, et al. A PDGFRalpha-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat Commun. 2018;9(1):3116 PMCID: PMC6078993.
46. Oliva CR, Halloran B, Hjelmeland AB, et al. IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling. Cell Commun Signal. 2018;16(1):61 PMCID: PMC6148802.
47. Stathias V, Jermakowicz AM, Maloof ME, et al. Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun. 2018;9(1):5315 PMCID: PMC6294341.
48. Chen JE, Pedron S, Shyu P, et al. Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater. 2018;5 PMCID: PMC6300158.
49. Gupta SK, Smith EJ, Mladek AC, et al. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Front Oncol. 2018;8:670 PMCID: PMC6349736.
50. Chen X, Zhang M, Gan H, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9(1):2949 PMCID: PMC6063898.
51. Sarkaria JN, Hu LS, Parney IF, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018;20(2):184-91 PMCID: PMC5777482.
52. Kurokawa C, Iankov ID, Anderson SK, et al. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. JNCI: Journal of the National Cancer Institute. 2018;110(10):1123-32.
53. Kim M, Ma DJ, Calligaris D, et al. Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier. Molecular Cancer Therapeutics. 2018;17(9):1893-901.
54. Laramy JK, Kim M, Gupta SK, et al. Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. The Journal of pharmacology and experimental therapeutics. 2017;363(2):136-47 PMCID: 5625285.
55. Kizilbash SH, Gupta SK, Chang K, et al. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Molecular cancer therapeutics. 2017;16(12):2735-46 PMCID: 5716902.
56. Cosset E, Ilmjarv S, Dutoit V, et al. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer cell. 2017;32(6):856-68 e5 PMCID: 5730343.
57. Pedron S, Polishetty H, Pritchard AM, et al. Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics. MRS Commun. 2017;7(3):442-9 PMCID: 5721678.
58. Karpel-Massler G, Ishida CT, Bianchetti E, et al. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nature communications. 2017;8(1):1067 PMCID: 5651864.
59. Pokorny JL, Calligaris D, Gupta SK, et al. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(8):1916-24 PMCID: 4401631.
60. Pastori C, Kapranov P, Penas C, et al. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci U S A. 2015;112(27):8326-31 PMCID: 4500283.
61. Zhang L, Zhang Z, Mason RP, Sarkaria JN, Zhao D. Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs. Scientific reports. 2015;5:9874 PMCID: 4428068.
62. Feng H, Li Y, Yin Y, et al. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor alpha. Neuro-oncology. 2015;17(6):832-42 PMCID: 4483118.
63. Curran TG, Zhang Y, Ma DJ, Sarkaria JN, White FM. MARQUIS: a multiplex method for absolute quantification of peptides and posttranslational modifications. Nature communications. 2015;6:5924 PMCID: 4293043.
64. Johnson J, Ascierto ML, Mittal S, et al. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. Journal of translational medicine. 2015;13:306 PMCID: 4574608.
65. Kitange GJ, Mladek AC, Schroeder MA, et al. Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Rep. 2016;14(11):2587-98 PMCID: 4805508.
66. Tuncbag N, Milani P, Pokorny JL, et al. Network Modeling Identifies Patient-specific Pathways in Glioblastoma. Scientific reports. 2016;6:28668 PMCID: 4926112.
67. Karpel-Massler G, Banu MA, Shu C, et al. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Oncotarget. 2016;7(11):12791-805 PMCID: 4914322.
68. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-8 PMCID: 3083463.
69. Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012;28(16):2184-5.
70. Wang C, Davila JI, Baheti S, et al. RVboost: RNA-seq variants prioritization using a boosting method. Bioinformatics. 2014;30(23):3414-6 PMCID: 4296157.
71. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923-30.
72. Kim D, Pertea G, Trapnell C, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36 PMCID: 4053844.
73. Lewis-Tuffin LJ, Feathers R, Hari P, et al. Src family kinases differentially influence glioma growth and motility. Molecular oncology. 2015.
74. Booth L, Roberts JL, Tavallai M, et al. OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies. J Cell Physiol. 2015;230(8):1982-98.
75. Garner JM, Ellison DW, Finkelstein D, et al. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations. PloS one. 2015;10(5):e0125838 PMCID: 4425556.
76. Chong DQ, Toh XY, Ho IA, et al. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC cancer. 2015;15(1):255 PMCID: 4408574.
77. Zhu S, Kisiel W, Lu YJ, et al. Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. J Drug Target. 2015;23(3):257-65.
78. Nakamura T, Peng K-W, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005;23(2):209-14.
79. Yu C, Friday BB, Lai J-P, et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics. 2006;5(9):2378-87.
80. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110 PMCID: NIHMS166306 PMC2818769.
81. Zhu X, Bidlingmaier S, Hashizume R, et al. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Molecular Cancer Therapeutics. 2010;9(7):2131-41 PMCID: NIHMS231497 PMC2944778.
82. Feng H, Hu B, Liu K-W, et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRalpha-stimulated glioma tumorigenesis in mice and humans. J Clin Invest. 2011;121(12):4670-84 PMCID: PMC3223070.
83. Feng H, Hu B, Jarzynka MJ, et al. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci U S A. 2012;109(8):3018-23 PMCID: PMC3286964.
84. Opyrchal M, Allen C, Iankov I, et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther. 2012;23(4):419-27 PMCID: PMC3327604.
85. Toussaint LG, 3rd, Nilson AE, Goble JM, et al. Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Molecular Cancer. 2012;11:32 PMCID: PMC3407025.
86. Cheng CK, Gustafson WC, Charron E, et al. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proc Natl Acad Sci U S A. 2012;109(31):12722-7 PMCID: PMC3411950.
87. Fenton TR, Nathanson D, Ponte de Albuquerque C, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012;109(35):14164-9 PMCID: PMC3435194.
88. Chen P-Y, Ozawa T, Drummond DC, et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro-oncology. 2013;15(2):189-97 PMCID: PMC3548589 [Available on 02/01/14].
89. Guvenc H, Pavlyukov MS, Joshi K, et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res. 2013;19(3):631-42.
90. Takahashi R, Giannini C, Sarkaria JN, et al. p53 isoform profiling in glioblastoma and injured brain. Oncogene. 2013;32(26):3165-74.
91. Pluquet O, Dejeans N, Bouchecareilh M, et al. Posttranscriptional regulation of PER1 underlies the oncogenic function of IREalpha. Cancer Res. 2013;73(15):4732-43.
92. Flavahan WA, Wu Q, Hitomi M, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 2013;16(10):1373-82.
93. Nathanson DA, Gini B, Mottahedeh J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72-6.
94. Choi JW, Schroeder MA, Sarkaria JN, Bram RJ. Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells. Cancer Res. 2014;74(2):484-96 PMCID: NIHMS544757
95. Grogan PT, Sarkaria JN, Timmermann BN, Cohen MS. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs. 2014;32(4):604-17.
96. Shing JC, Choi JW, Chapman R, et al. A novel synthetic 1,3-phenyl bis-thiourea compound targets microtubule polymerization to cause cancer cell death. Cancer Biology & Therapy. 2014;15(7):895-905 PMCID: PMC4100990 [Available on 07/01/15].
97. Kushwaha D, Ramakrishnan V, Ng K, et al. A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget. 2014;5(12):4026-39 PMCID: PMC4147303.
98. Zhang Y, Farenholtz KE, Yang Y, et al. Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19(6):1433-44 PMCID: 3602223.
99. Zhang J, van Zijl PC, Laterra J, et al. Unique patterns of diffusion directionality in rat brain tumors revealed by high-resolution diffusion tensor MRI. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 2007;58(3):454-62 PMCID: 3715744.
100. Yu C, Friday BB, Yang L, et al. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro-oncology. 2008;10(3):309-19.
101. Yang L, Clarke MJ, Carlson BL, et al. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(12):3993-4001 PMCID: 3972037.
102. Yacoub A, Park MA, Hanna D, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol. 2006;70(2):589-603.
103. Yacoub A, Mitchell C, Hong Y, et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer biology & therapy. 2004;3(8):739-51.
104. Yacoub A, Hamed H, Emdad L, et al. MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer biology & therapy. 2008;7(6):917-36.
105. Xue R, Behera P, Xu J, Viapiano MS, Lannutti JJ. Polydimethylsiloxane Core-Polycaprolactone Shell Nanofibers as Biocompatible, Real-Time Oxygen Sensors. Sens Actuators B Chem. 2014;192:697-707 PMCID: 4082658.
106. Wang S, Zhou J. Diffusion tensor magnetic resonance imaging of rat glioma models: a correlation study of MR imaging and histology. J Comput Assist Tomogr. 2012;36(6):739-44 PMCID: 3513798.
107. Wang E, Zhang C, Polavaram N, et al. The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PloS one. 2014;9(1):e86102 PMCID: 3900478.
108. Venkatesh HS, Chaumeil MM, Ward CS, et al. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro-oncology. 2012;14(3):315-25 PMCID: 3280799.
109. Tobias AL, Thaci B, Auffinger B, et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl Med. 2013;2(9):655-66 PMCID: 3754466.
110. Serwer LP, Noble CO, Michaud K, et al. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro-oncology. 2011;13(12):1288-95 PMCID: 3223095.
111. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Molecular cancer therapeutics. 2007;6(3):1167-74.
112. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(7 Pt 1):2264-71.
113. Robinson CG, Palomo JM, Rahmathulla G, et al. Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. Br J Cancer. 2010;103(4):498-504 PMCID: 2939788.
114. Prasad G, Sottero T, Yang X, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-oncology. 2011;13(4):384-92 PMCID: 3064692.
115. Park MA, Yacoub A, Rahmani M, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol. 2008;73(4):1168-84 PMCID: 2674576.
116. Oliva CR, Nozell SE, Diers A, et al. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. The Journal of biological chemistry. 2010;285(51):39759-67 PMCID: 3000957.
117. Michaud K, Solomon DA, Oermann E, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010;70(8):3228-38 PMCID: 2855904.
118. Liu C, Sarkaria JN, Petell CA, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(23):7155-65.
119. Lewis-Tuffin LJ, Rodriguez F, Giannini C, et al. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PloS one. 2010;5(10):e13665 PMCID: 2965143.
120. Kitange GJ, Mladek AC, Carlson BL, et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;18(15):4070-9 PMCID: 3716364.
121. Kitange GJ, Carlson BL, Schroeder MA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncology. 2009;11(3):281-91 PMCID: 2718972.
122. Kitange GJ, Carlson BL, Schroeder MA, et al. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J Neurooncol. 2010;100(2):177-86 PMCID: 3233976.
123. Kitange GJ, Carlson BL, Mladek AC, et al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol. 2009;92(1):23-31 PMCID: 2790867.
124. Huveldt D, Lewis-Tuffin LJ, Carlson BL, et al. Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PloS one. 2013;8(2):e56505 PMCID: 3572988.
125. Higgins DM, Wang R, Milligan B, et al. Brain tumor stem cell multipotency correlates with nanog expression and extent of passaging in human glioblastoma xenografts. Oncotarget. 2013;4(5):792-801 PMCID: 3742839.
126. Hashizume R, Ozawa T, Dinca EB, et al. A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol. 2010;96(2):151-9 PMCID: 2808534.
127. Guessous F, Zhang Y, diPierro C, et al. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem. 2010;10(1):28-35 PMCID: 3278215.
128. Guessous F, Alvarado-Velez M, Marcinkiewicz L, et al. Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol. 2013;112(2):153-63 PMCID: 3609924.
129. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncology. 2005;7(2):164-76 PMCID: 1871885.
130. Feng H, Hu B, Vuori K, et al. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 2014;33(19):2504-12 PMCID: 3883905.
131. Emdad L, Sarkar D, Lee SG, et al. Astrocyte elevated gene-1: a novel target for human glioma therapy. Molecular cancer therapeutics. 2010;9(1):79-88 PMCID: 3165052.
132. Dinca EB, Sarkaria JN, Schroeder MA, et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg. 2007;107(3):610-6.
133. Dinca EB, Lu KV, Sarkaria JN, et al. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res. 2008;68(24):10034-9 PMCID: 2987557.
134. Clarke MJ, Mulligan EA, Grogan PT, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Molecular cancer therapeutics. 2009;8(2):407-14 PMCID: 2692390.
135. Cen L, Carlson BL, Schroeder MA, et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro-oncology. 2012;14(7):870-81 PMCID: 3379801.
136. Cen L, Carlson BL, Pokorny JL, et al. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro-oncology. 2013;15(6):735-46 PMCID: 3661094.
137. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol. 2011;Chapter 14:Unit 14 6 PMCID: 3129784.
138. Carlson BL, Grogan PT, Mladek AC, et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys. 2009;75(1):212-9 PMCID: 2773462.
139. Candolfi M, Xiong W, Yagiz K, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A. 2010;107(46):20021-6 PMCID: 2993419.
140. Booth L, Roberts JL, Cruickshanks N, et al. Regulation of OSU-03012 toxicity by ER stress proteins and ER stress inducing drugs. Molecular cancer therapeutics. 2014.
141. Allen C, Paraskevakou G, Iankov I, et al. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther. 2008;16(9):1556-64 PMCID: 2748750.
142. Allen C, Opyrchal M, Aderca I, et al. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther. 2013;20(4):444-9 PMCID: 3509233.
143. Ahmed AU, Thaci B, Tobias AL, et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst. 2013;105(13):968-77 PMCID: 3699440.